In addition, intravitreal injections of anti-VEGF agents too frequently may also result in systemic adverse events or ocular complications, such as endophthalmitis, acute elevation of systemic blood pressure, and vitreous hemorrhage34 or even lead to systemic thrombotic events35. Here, VEGFA is linked to endophthalmitis.